Drugs for Hepatitis C Virus Infection
October 28, 2024 (Issue: 1714)
About 2.5 million persons in the US had hepatitis C
between 2017 and 2020. Guidelines from the American
Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society of America (IDSA)
on management of hepatitis C virus...more
- KC Lewis et al. Estimated prevalence and awareness of hepatitis C virus infection among US adults: National Health and Nutrition Examination Survey, January 2017 – March 2020. Clin Infect Dis 2023; 77:1413. doi:10.1093/cid/ciad411
- D Bhattacharya et al. Hepatitis C guidance 2023 update: American Association for the Study of Liver Diseases—Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2023 May 25 (epub). doi:10.1093/cid/ciad319
- D Guss et al. Diagnosis and management of hepatitis C infection in primary care settings. J Gen Intern Med 2018; 33:551. doi:10.1007/s11606-017-4280-y
- US Preventive Services Task Force. Final recommendation statement. Hepatitis C virus infection in adolescents and adults: screening. March 2, 2020. Available at: https://bit.ly/3Bh6hTq. Accessed October 9, 2024.
- S Schillie et al. CDC recommendations for hepatitis C screening among adults – United States, 2020. MMWR Recomm Rep 2020; 69:1. doi:10.15585/mmwr.rr6902a1
- CE Ruhl and JE Everhart. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129:1928. doi:10.1053/j.gastro.2005.08.056
- MP Carrieri et al. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. J Hepatol 2017; 67:1157. doi:10.1016/j.jhep.2017.08.005
- FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. October 4, 2016. Available at: https://bit.ly/3MXYzjq. Accessed October 9, 2024.
- Mavyret and Vosevi – two new combinations for chronic HCV infection. Med Lett Drugs Ther 2017; 59:166.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Sofosbuvir/velpatasvir (Epclusa) for hepatitis C. Med Lett Drugs Ther 2016; 58:107.
- FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug. March 24, 2015. Available at: https://bit.ly/4gDByzV. Accessed October 9, 2024.
- In brief: New indications for Harvoni. Med Lett Drugs Ther 2016; 58:6.
- Elbasvir/grazoprevir (Zepatier) for hepatitis C. Med Lett Drugs Ther 2016; 58:25.
- N Reau et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology 2018; 68:1298. doi:10.1002/hep.30046
- K Agarwal et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. J Hepatol 2018; 69:603. doi:10.1016/j.jhep.2018.05.039
- M Colombo et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med 2017; 166:109. doi:10.7326/m16-1205
- AE Woolley et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. N Engl J Med 2019; 380:1606. doi:10.1056/nejmoa1812406
- M Cypel et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. Lancet Respir Med 2020; 8:192. doi:10.1016/s2213-2600(19)30268-1
- M AbdAllah et al. Pregnancy outcome of anti-HCV direct-acting antivirals: real-life data from an Egyptian cohort. Liver Int 2021; 41:1494. doi:10.1111/liv.14913
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Sofosbuvir. [Updated 2023 September 15]. Available at: https://bit.ly/4gD3XpO. Accessed October 9, 2024.
- Q-L Zeng et al. Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: a case series study. J Med Virol 2022; 94:4548. doi:10.1002/jmv.27877
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Ribavirin. [Updated 2023 September 15]. Available at: https://bit.ly/3ZBefB0. Accessed October 9, 2024.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
